Jabs could slow ageing, researchers say

[Pelican Press 0]

This is the hidden content, please

• Sign In
• or
• Sign Up

Jabs could slow ageing, researchers say

A ***** used to treat Type 2 diabetes and obesity could also slow down the process of ageing, researchers believe.

Semaglutide, better known as Ozempic, “has far-reaching benefits beyond what we initially imagined,” Prof Harlan Krumholz, from the Yale School of Medicine, said following the publication of several new studies.

They found that the ***** could be used to treat a wide range of illnesses linked to heart ********, arthritis, Alzheimer’s and even *******.

“It wouldn’t surprise me that improving people’s health this way actually slows down the ageing process,” Prof Krumholz was quoted on Friday as telling the ********* Society of Cardiology Conference 2024, where the studies were presented.

The new data has been published in a number of medical journals, including the Journal of the ********* College of Cardiology (JACC), which Prof Krumholz edits.

“These ground-breaking medications are poised to revolutionise cardiovascular care and could dramatically enhance cardiovascular health,” he said.

The studies – part of the

This is the hidden content, please

• Sign In
• or
• Sign Up

– tracked more than 17,600 people, aged 45 or older, as they were given either 2.4 mg of semaglutide or a placebo for more than three years.

Participants were obese or overweight and had cardiovascular ******** but not diabetes.

Those who took the ***** ***** at a lower rate from all causes, including cardiovascular issues and Covid-19, researchers found.

People using the weight-loss ***** were just as likely to catch Covid but they were less likely to **** from it, with 2.6% dying among those on semaglutide compared with 3.1% on the placebo.

And while women experienced fewer major adverse cardiovascular events, the ***** “consistently reduced the risk” of adverse cardiovascular outcomes regardless of ****.

It also improved heart ******** symptoms and cut levels of inflammation in the body regardless of whether or not people lost weight.

Dr Benjamin Scirica, lead author of one of the studies and a professor of cardiovascular medicine at Harvard Medical School, said the findings “reinforce that overweight and obesity increases the risk of ****** due to many etiologies”.

But, he told the PA news agency, this “can be modified with potent incretin-based therapies like semaglutide”.

The medication is a prescription ***** offered by the NHS, which supresses appetite and is sold under the brand names Wegovy – used to treat obesity – and Ozempic, for diabetes.

It comes in the form of an injection and mimics the hormone GLP-1, making people feel fuller and less hungry.

Experts have

This is the hidden content, please

• Sign In
• or
• Sign Up

that the ***** is not a quick fix or a replacement for eating well and exercising, and should only be offered under medical supervision.

Like any medication, there can be side effects and risks – the most common being nausea, an upset stomach, bloating and gas.

This is the hidden content, please

• Sign In
• or
• Sign Up

#Jabs #slow #ageing #researchers

This is the hidden content, please

• Sign In
• or
• Sign Up

This is the hidden content, please

• Sign In
• or
• Sign Up